Portal de Periódicos da CAPES

RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral

2022; Springer Science+Business Media; Volume: 12; Issue: 11 Linguagem: Inglês

10.1002/ctm2.1098

2001-1326

Sidharth Jain, Samantha Rego, Steven Park, Yiran Liu, Simone Parn, Kush Savsani, David S. Perlin, Sivanesan Dakshanamurthy,

RNA regulation and disease

Dear Editor, In this study, we found gene expression changes in key genes involved in activating immune pathways and genes targeted by SARS-CoV-2 to interfere with normal host cell functioning. Notably, critical changes have been observed in Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2 (EIF2AK2), which plays an important role in activating the interferon response and interfering with host cell translational machinery in SARS-CoV-2 infection,1-3 presenting a prospective therapeutic target. We demonstrated the therapeutic antiviral effect of the EIF2AK2 with its inhibitor compound C16, which showed strong antiviral potency in multiple antiviral assays. We analysed the RNAseq data of human lung or respiratory tract samples from patients infected by COVID-19. Our search of the Gene Expression Omnibus (GEO) database revealed four RNAseq data sets that met the inclusion criteria for the study. We identified 509 eligible patient RNAseq samples from GEO from GSE152075, GSE147057 and GSE150316 data sets (Supplementary Material), which were analysed using the Partek Flow genomics suite. Our differential gene expression analysis revealed several target genes and pathways that have been well described in SARS-CoV-2 pathogenesis, including the ACE2/TMPRSS2 surface receptors used for viral entry and interferon response and host translation machinery. Our drug–gene interaction analysis identified drugs, such as ribavirin and colchicine, which have been experimentally tested or are already in use to treat COVID-19 patients,4, 5 validating the significance of our study. We showed that the interferon signalling pathway was entirely upregulated, revealing many key genes responsible for activating the interferon response in SARS-CoV-2 infection (Figure 1A). At an individual gene-level analysis, multiple ribosomal proteins were significantly downregulated in each data set (Figure 1B). Specifically, the expression of 40S and 60S ribosomal subunit proteins were significantly downregulated, suggesting that viral proteins interact with and modulate the expression of host translation machinery with SARS-CoV-2 infection. The eukaryotic initiation factor 2 (eIF2) signalling pathway was among the most downregulated pathways (Figure S4), which is shown to be involved in viral replication and transcription of viral genomic material. An important hub of this pathway is EIF2AK2, a kinase that is responsible for activating the inflammasome that was significantly upregulated in both analysed data sets (Figure 1). Along with suppressing ribosomal gene expression, EIF2AK2 acts as part of the cellular immune response to SARS-CoV-2, leading to downregulation and halt in host translation machinery. EIF2AK2 is involved in producing proinflammatory cytokines and inhibits the eIF2 pathway (Figure 1), suggesting that SARS-CoV-2 can impair host antiviral response with multiple mechanisms by acting on EIF2AK2. These findings led us to investigate the potential efficacy of the PKR (EIF2AK2) inhibitor to reverse the phenotype induced by SARS-CoV-2 infection. To further investigate the role of EIF2AK2 in the context of SARS-CoV-2 infection, an in vitro assay of EIF2AK2 inhibitor was performed. The EIF2AK2 inhibitor compound imidazolo-oxindole C16, hereafter referred to as C16, has been shown to antagonise the kinase activity of PKR6 by binding to the ATP site. To support our findings, in multiple assays, we consistently demonstrated a substantial inhibitory effect of C16 on viral proliferation in SARS-CoV-2-infected cells (Table 1). Compared to remdesivir, C16 showed relatively high potency in the 48H direct virus inhibition assay (EC50 = 1.25 μM) and the 72H ATP luminescence assay measuring cytopathic effect (EC50 = 2.96 μM) in A549+ACE2 cells (Figure 2A–C). Similarly, C16 antiviral activity was observed in the VeroE6 cells overexpressing TMPRSS2, a serine protease essential for SARS-CoV2 cell entry (Figure 2D–F). The combination treatment of remdesivir + C16 showed a low to moderate synergism effect on VeroE6 cells with a reported EC50 value of 650 nM in the 48H direct virus inhibition assay and 1.51 M in the 72H CPE assay (Figure 2G and H). Krähling et al.7 and others8, 9 demonstrated that in the infected cells, SARS-CoV activates PKR, leading to sustained phosphorylation of eIF2α and suppression of host translation. Thus, our data present EIF2AK2 kinase as a viable drug target for therapies to target viral translation and also to modulate the host interferon response. To understand the association of the host EIF2AK2 hub interactions with the SARS-CoV-2 proteins, we mapped the interaction of EIF2AK2 with the viral SARS-CoV-2 Nucleocapsid protein (N) interactions based on physical evidence (BioGrid database) correlating to our identified significantly up- and downregulated differentially expressed genes. Notably, we found that the N protein interacts with EIF2AK2 (Figure 3A), in addition to a group of interferon-induced proteins (IFIT2, IFIT3, IFIT5) (Figure 3B), which contribute to the dysregulation of innate immunity of the infected COVID-19 patients. Our structural modelling analysis found that the C16 compound binds at the SARS-CoV-2 N protein nucleotide-binding pocket NTD domain (Figure 3C). Notably, Lin et al.10 reported a cocrystal structure of HCoV-OC43 coronavirus N protein inhibitor PJ34 targeting the same high sequence similarity nucleotide-binding pocket (PDB:4KXJ). Thus, we speculate that C16 could act as a dual inhibitor of viral N protein and host EIF2AK2. Blocking the formation of the N protein interactome can potentially inhibit viral protein replication and protein synthesis and restore the IFN pathway. This study has limitations. The availability of data at the time of analysis limited the scope of our study – namely, the lack of comprehensive clinical annotations regarding treatment or disease severity and the presence of low-quality sequencing data. Information about drug toxicity, efficacy and clinical applicability is needed to further validate the drugs, compounds, and other therapeutics identified in our analysis. In this study, we identified EIF2AK2 as a potential antiviral target. In multiple in vitro assays, we demonstrated that EIF2AK2 inhibitor compound C16 is a potent antiviral that could combat SARS-CoV-2 infection. We also found that C16 binds to an EIF2AK2 hub interacting protein, the SARS-CoV-2 N protein, thus could act as a dual inhibitor, conferring strong SARS-CoV-2 antiviral activity. Our results suggest new potential targets that have not been well-characterised that warrant further investigation. These host therapeutic targets can help guide drug discovery efforts towards those most indicated by COVID-19 disease signatures. While many studies have focused on potential therapeutics to target viral proteins, our analysis of important host factors contributing to disease pathogenesis provides necessary insight for more patient-focused therapeutic strategies based on host factors and disease severity. Sivanesan Dakshanamurthy: conceptualisation, methodology, supervision, investigation, writing – reviewing and editing. Sidharth Jain: methodology, investigation, data curation, writing – reviewing and editing. Samantha Rego: methodology, investigation, data curation, writing – reviewing and editing. Steven Park: methodology, investigation, writing- reviewing and editing. Yiran liu: visualisation, investigation, writing – reviewing and editing. Simone Parn: investigation, visualisation, writing- reviewing and editing. Kush Savsani: investigation, visualisation, writing – reviewing and editing. David Perlin: investigation, writing – reviewing and editing. We wish to acknowledge the Georgetown University Medical Center for the COVID19 pilot award. This work was supported in part by funding from Georgetown Lombardi's Cancer Research Training and Education Coordination (CRTEC), and the authors (SD, SR, SP and KS) were part of the GLCCC Undergraduate Summer Research Program. The authors have no conflict of interest to declare. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.